Edition:
United States

Cesca Therapeutics Inc (KOOL.OQ)

KOOL.OQ on NASDAQ Stock Exchange Capital Market

3.61USD
20 Jul 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.61
Open
$3.62
Day's High
$3.62
Day's Low
$3.62
Volume
59
Avg. Vol
16,222
52-wk High
$7.39
52-wk Low
$2.45

Latest Key Developments (Source: Significant Developments)

Cesca Therapeutics says acquires cell processing systems of SynGen
Monday, 10 Jul 2017 07:45am EDT 

July 10 (Reuters) - Cesca Therapeutics Inc :Cesca therapeutics acquires the cell processing systems of syngen under asset acquisition agreement.Cesca therapeutics inc - wholly-owned subsidiary, thermogenesis corp., has entered into an asset acquisition agreement with syngen inc.Cesca therapeutics inc- ‍wholly-owned subsidiary, thermogenesis corp., has entered into an asset acquisition agreement with syngen inc​.Cesca therapeutics inc- ‍representative of syngen's majority shareholder, bay city capital, has joined board of directors of themogenesis​.Cesca therapeutics - philip coelho, co-founder and cto of syngen, has joined thermogenesis in chief technology officer role, effective immediately.Cesca therapeutics inc- ‍in exchange for assets, thermogenesis granted syngen 20% of its common stock and paid a one-time cash payment of $1 million​.  Full Article

Cesca Therapeutics Q3 loss per share $0.21
Thursday, 11 May 2017 04:16pm EDT 

May 11 (Reuters) - Cesca Therapeutics Inc ::Cesca Therapeutics announces fiscal third quarter and nine month 2017 financial and operating results and provides corporate update.Q3 revenue $3.3 million versus $2.8 million.Q3 loss per share $0.21.  Full Article

Cesca Therapeutics announces closing of $5 mln revolving line of credit
Monday, 13 Mar 2017 06:00am EDT 

Cesca Therapeutics Inc - : Cesca Therapeutics announces closing of $5 million revolving line of credit . Has set-up a wholly-owned subsidiary, Thermogenesis Corp, to separately own and operate its device business . Clinical development activities will remain with cesca, parent company ."Our goal is to make thermogenesis cash-flow neutral within next 12 months".  Full Article

Cesca Therapeutics Q2 revenue rose 22 percent to $4.0 mln
Monday, 13 Feb 2017 04:05pm EST 

Cesca Therapeutics Inc : Cesca therapeutics reports second quarter fiscal 2017 financial results and provides business update . Q2 revenue rose 22 percent to $4.0 million .Says net loss was $3.4 million for three months ended december 31, 2016.  Full Article

Cesca Therapeutics files for resale of up to 950,000 common shares
Friday, 20 Jan 2017 02:09pm EST 

Cesca Therapeutics Inc : Files for resale of up to 950,000 shares of co's common stock by the selling stockholders - sec filing .Co will not receive any of the proceeds from the sale of the shares by the selling stockholders.  Full Article

Cesca Therapeutics reports first quarter fiscal 2017 results and provides business update
Thursday, 17 Nov 2016 04:05pm EST 

Cesca Therapeutics Inc : Cesca Therapeutics reports first quarter fiscal 2017 results and provides business update . Cesca Therapeutics Inc says net loss was $22.4 million for three months ended September 30, 2016, compared to $3.4 million for corresponding fiscal 2016 period .Q1 revenue $3.8 million versus $2.8 million.  Full Article

Empery Asset Management LP reports 5.43 pct passive stake in Cesca Therapeutics
Monday, 15 Aug 2016 05:19pm EDT 

Cesca Therapeutics Inc : Empery Asset Management, LP reports 5.43 pct passive stake in Cesca Therapeutics as of August 4, 2016 - SEC Filing Source - http://bit.ly/2bl8rAM Further company coverage: [KOOL.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Cesca Therapeutics announces pricing of $2.5 mln registered direct offering
Thursday, 4 Aug 2016 09:08am EDT 

Cesca Therapeutics Inc: Cesca Therapeutics announces pricing of $2.5 million registered direct offering .To purchase 600,000 shares of common stock at a purchase price per share of $4.10.  Full Article

Cesca Therapeutics files for mixed shelf of up to $30 mln
Wednesday, 29 Jun 2016 05:21pm EDT 

Cesca Therapeutics Inc :Files for mixed shelf of up to $30.0 million - SEC filing.  Full Article

Cesca Therapeutics submits investigational device exemption supplement for Surgwerks CLI pivotal trial
Wednesday, 1 Jun 2016 11:15am EDT 

Cesca Therapeutics Inc: Cesca therapeutics submits investigational device exemption supplement for Surgwerks CLI pivotal trial .Expects FDA to submit its response to IDE supplement within 30 days of submission.  Full Article

BRIEF-Cesca Therapeutics says acquires cell processing systems of SynGen

* Cesca therapeutics acquires the cell processing systems of syngen under asset acquisition agreement